AVROBIO Executives
AVRODelisted Stock | USD 1.40 0.04 2.78% |
AVROBIO employs about 13 people. The company is managed by 12 executives with a total tenure of roughly 31 years, averaging almost 2.0 years of service per executive, having 1.08 employees per reported executive. Analysis of AVROBIO's management performance can provide insight into the firm performance.
AVROBIO |
AVROBIO Management Team Effectiveness
The company has return on total asset (ROA) of (0.3518) % which means that it has lost $0.3518 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4273 %, meaning that it created $0.4273 on every $100 dollars invested by stockholders. AVROBIO's management efficiency ratios could be used to measure how well AVROBIO manages its routine affairs as well as how well it operates its assets and liabilities.AVROBIO Workforce Comparison
AVROBIO is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 108. AVROBIO retains roughly 13.0 in number of employees claiming about 12% of equities under Health Care industry.
AVROBIO Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AVROBIO insiders, such as employees or executives, is commonly permitted as long as it does not rely on AVROBIO's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AVROBIO insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leonard Braden Michael over six months ago Acquisition by Leonard Braden Michael of 296882 shares of AVROBIO at 1.3 subject to Rule 16b-3 | ||
Steven Avruch over six months ago Acquisition by Steven Avruch of 32834 shares of AVROBIO subject to Rule 16b-3 | ||
Erik Ostrowski over six months ago Exercise or conversion by Erik Ostrowski of 40084 shares of AVROBIO subject to Rule 16b-3 | ||
Erik Ostrowski over a year ago Acquisition by Erik Ostrowski of 70000 shares of AVROBIO subject to Rule 16b-3 | ||
Christopher Paige over a year ago Acquisition by Christopher Paige of 17643 shares of AVROBIO subject to Rule 16b-3 | ||
Geoff MacKay over a year ago Exercise or conversion by Geoff MacKay of 45999 shares of AVROBIO subject to Rule 16b-3 | ||
Geoff MacKay over a year ago Acquisition by Geoff MacKay of 300667 shares of AVROBIO subject to Rule 16b-3 |
AVROBIO Notable Stakeholders
An AVROBIO stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AVROBIO often face trade-offs trying to please all of them. AVROBIO's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AVROBIO's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Erik MBA | Interim President | Profile | |
Monique Silva | Sr Communications | Profile | |
Deanna MBA | Chief Officer | Profile | |
Geoff BSc | President, Founder | Profile | |
Steven JD | Chief Secretary | Profile | |
Andreas Kouri | Senior Manufacturing | Profile | |
MD FFPM | Chief Officer | Profile | |
Kirsten Dupuis | Chief Staff | Profile | |
Azadeh Golipour | Chief Officer | Profile | |
Matthew Arnold | Head Operations | Profile | |
Jeffrey Medin | Scientific Founder | Profile | |
Scott Gottesman | Vice Resource | Profile |
About AVROBIO Management Performance
The success or failure of an entity such as AVROBIO often depends on how effective the management is. AVROBIO management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AVROBIO management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AVROBIO management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Avrobio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
AVROBIO Workforce Analysis
Traditionally, organizations such as AVROBIO use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AVROBIO within its industry.AVROBIO Manpower Efficiency
Return on AVROBIO Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Income Per Employee | 935.2K | |
Net Income Per Executive | 1M | |
Working Capital Per Employee | 7.2M | |
Working Capital Per Executive | 7.8M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in AVROBIO Stock
If you are still planning to invest in AVROBIO check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVROBIO's history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |